Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has proved helpful conscientiously but unsuccessfully to produce a single therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be being used is actually an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as a combination therapy in the treatment of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my past few shares. My first CytoDyn post, “CytoDyn: What To Do When It is Too Good to be able to Be True?”, set away the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan offered such an extremely marketing picture in the Uptick Newswire interview that I came away with an inadequate opinion of the company.

Irony of irony, my bad viewpoint of the business has grown steadily, yet the disappointment hasn’t been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger yet still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your therapy and prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity in HIV- infected subjects. Today’s payment of $3.5 million transfers ownership of the expertise and also associated intellectual property coming from Progenics to CytoDyn, and roughly twenty five million mg of bulk drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 zillion) along with the very first new drug application approval ($5 million), and also royalty payments of five percent of net sales after commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to acquire a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and many therapies, it has this single remedy in addition to a “broad pipeline of indications” since it places it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely advantageous therapy of dozens of indications.

Its opening banner on its site (below) shows an energetic organization with diverse interests albeit centered on leronlimab, several illness types, multiple publications and multiple presentations.

Can it all be smoke cigarettes and mirrors? That’s a question I’ve been asking myself from the very beginning of the interest of mine in this particular business. Judging with the multiples of a huge number of various commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this particular question.

CytoDyn is a classic battleground, or perhaps some could say cult stock. Its adherents are fiercely protective of its prospects, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *